A prospective, randomised, phase II study of horse antithymocyte globulin vs rabbit antithymocyte globulin as immune-modulating therapy in patients with low-risk myelodysplastic syndromes.

Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood (2013) 2.97

Alemtuzumab treatment of intermediate-1 myelodysplasia patients is associated with sustained improvement in blood counts and cytogenetic remissions. J Clin Oncol (2010) 1.79

IDH1 mutations in patients with myelodysplastic syndromes are associated with an unfavorable prognosis. Haematologica (2010) 1.32

Efficacy of rabbit anti-thymocyte globulin in severe aplastic anemia. Haematologica (2011) 1.07

Current therapy of myelodysplastic syndromes. Blood Rev (2013) 1.07

Phase II study of rabbit anti-thymocyte globulin, cyclosporine and granulocyte colony-stimulating factor in patients with aplastic anemia and myelodysplastic syndrome. Leukemia (2009) 1.04

Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses. Ann Hematol (2006) 1.00

Immunologic aspects of hypoplastic myelodysplastic syndrome. Semin Oncol (2011) 0.98

Rare occurrence of DNMT3A mutations in myelodysplastic syndromes. Haematologica (2011) 0.97

Autoimmune mechanisms in the pathophysiology of myelodysplastic syndromes and their clinical relevance. Haematologica (2009) 0.94

Immunosuppression for myelodysplastic syndrome: how bench to bedside to bench research led to success. Hematol Oncol Clin North Am (2010) 0.92

Immunological derangement in hypocellular myelodysplastic syndromes. Transl Med UniSa (2014) 0.89

Comparison of horse and rabbit antithymocyte globulin in immunosuppressive therapy for refractory cytopenia of childhood. Haematologica (2013) 0.87

Anti-thymocyte globulin plus etanercept as therapy for myelodysplastic syndromes (MDS): a phase II study. Br J Haematol (2010) 0.87

Thymoglobulin--new approaches to optimal outcomes. J Med Life (2010) 0.85

Final results of the phase II study of rabbit anti-thymocyte globulin, ciclosporin, methylprednisone, and granulocyte colony-stimulating factor in patients with aplastic anaemia and myelodysplastic syndrome. Br J Haematol (2012) 0.83

Immune dysregulation in myelodysplastic syndrome. Hematol Rep (2010) 0.82

T-cell receptor Vβ skewing frequently occurs in refractory cytopenia of childhood and is associated with an expansion of effector cytotoxic T cells: a prospective study by EWOG-MDS. Blood Cancer J (2014) 0.82

A phase II multicenter rabbit anti-thymocyte globulin trial in patients with myelodysplastic syndromes identifying a novel model for response prediction. Haematologica (2014) 0.81

Management of myelodysplastic syndromes: 2008 update. Oncology (Williston Park) (2008) 0.81

Predicting survival of patients with hypocellular myelodysplastic syndrome: development of a disease-specific prognostic score system. Cancer (2012) 0.79

Abnormalities of the alphabeta T-cell receptor repertoire in advanced myelodysplastic syndrome. Exp Hematol (2009) 0.79

Immunomodulatory treatment of myelodysplastic syndromes: antithymocyte globulin, cyclosporine, and alemtuzumab. Semin Hematol (2012) 0.77

Advances in haematological pharmacotherapy in 21st century. Indian J Hematol Blood Transfus (2010) 0.75

International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood (1997) 20.41

T cell stimulation by staphylococcal enterotoxins. Clonally variable response and requirement for major histocompatibility complex class II molecules on accessory or target cells. J Exp Med (1988) 3.90

Haemopoietic growth factors in aplastic anaemia: a cautionary note. European Bone Marrow Transplant Working Party for Severe Aplastic Anaemia. Lancet (1994) 3.24

Matrix program to analyze primary structure homology. Nucleic Acids Res (1982) 3.10

Quality assurance in immunohistochemistry: results of an interlaboratory trial involving 172 pathologists. Am J Surg Pathol (2002) 3.05

Early molecular and cytogenetic response is predictive for long-term progression-free and overall survival in chronic myeloid leukemia (CML). Leukemia (2012) 2.78

Randomized comparison of interferon-alpha with busulfan and hydroxyurea in chronic myelogenous leukemia. The German CML Study Group. Blood (1994) 2.78

Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood (2001) 2.50

Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group. N Engl J Med (1991) 2.40

TIF1gamma, a novel member of the transcriptional intermediary factor 1 family. Oncogene (1999) 2.05

Congenital dyserythropoietic anemia with karyorrhexis and multinuclearity of erythroblasts. Helv Med Acta (1968) 2.02

Clinical, morphological, cytogenetic, and prognostic features of patients with myelodysplastic syndromes and del(5q) including band q31. Leukemia (2004) 1.90

The myelodysplastic/myeloproliferative neoplasms: myeloproliferative diseases with dysplastic features. Leukemia (2008) 1.89

Prospective randomized multicenter study comparing cyclosporin alone versus the combination of antithymocyte globulin and cyclosporin for treatment of patients with nonsevere aplastic anemia: a report from the European Blood and Marrow Transplant (EBMT) Severe Aplastic Anaemia Working Party. Blood (1999) 1.88

Diagnostic workup of patients with acquired von Willebrand syndrome: a retrospective single-centre cohort study. J Thromb Haemost (2008) 1.80

Peripheral blood tyrosinase messenger RNA detection and survival in malignant melanoma. J Natl Cancer Inst (1996) 1.79

Aetiology and clinical significance of thrombocytosis: analysis of 732 patients with an elevated platelet count. J Intern Med (1999) 1.79

Prethymic phenotype and genotype of pre-T (CD7+/ER-)-cell leukemia and its clinical significance within adult acute lymphoblastic leukemia. Blood (1989) 1.74

High-dose cytarabine and mitoxantrone in consolidation therapy for acute promyelocytic leukemia. Leukemia (2005) 1.72

Sequential combination of azacitidine and lenalidomide in del(5q) higher-risk myelodysplastic syndromes or acute myeloid leukemia: a phase I study. Leukemia (2013) 1.71

Acute effects of recombinant human interleukin-6 on endocrine and central nervous sleep functions in healthy men. J Clin Endocrinol Metab (1998) 1.70

Treatment of Adult ALL according to protocols of the German Multicenter Study Group for Adult ALL (GMALL). Hematol Oncol Clin North Am (2000) 1.69

Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults. Blood (1988) 1.69

Empirical potentials and functions for protein folding and binding. Curr Opin Struct Biol (1997) 1.66

Effectiveness of immunosuppressive therapy in older patients with aplastic anemia. European Group for Blood and Marrow Transplantation Severe Aplastic Anaemia Working Party. Ann Intern Med (1999) 1.65

Individual patient data-based meta-analysis of patients aged 16 to 60 years with core binding factor acute myeloid leukemia: a survey of the German Acute Myeloid Leukemia Intergroup. J Clin Oncol (2004) 1.62

Analysis of factors contributing to higher erythropoietin levels in patients with chronic liver disease. Scand J Gastroenterol (2004) 1.60

Problems in the classification of CMML--dysplastic versus proliferative type. Leuk Res (1998) 1.60

Glycoprotein VI is a major collagen receptor for platelet activation: it recognizes the platelet-activating quaternary structure of collagen, whereas CD36, glycoprotein IIb/IIIa, and von Willebrand factor do not. Blood (1998) 1.59

Host-specific interleukin-2-secreting donor T-cell precursors as predictors of acute graft-versus-host disease in bone marrow transplantation between HLA-identical siblings. N Engl J Med (1992) 1.59

Treatment of acquired severe aplastic anemia: bone marrow transplantation compared with immunosuppressive therapy--The European Group for Blood and Marrow Transplantation experience. Semin Hematol (2000) 1.59

A pilot study of bendamustine in elderly patients with high-risk MDS and AML. Leuk Lymphoma (2007) 1.58

Cyclosporine A and mycophenolate mofetil vs cyclosporine A and methotrexate for graft-versus-host disease prophylaxis after stem cell transplantation from HLA-identical siblings. Bone Marrow Transplant (2005) 1.57

Standardization of flow cytometry in myelodysplastic syndromes: a report from an international consortium and the European LeukemiaNet Working Group. Leukemia (2012) 1.57

Double induction strategy for acute myeloid leukemia: the effect of high-dose cytarabine with mitoxantrone instead of standard-dose cytarabine with daunorubicin and 6-thioguanine: a randomized trial by the German AML Cooperative Group. Blood (1999) 1.56

Etiology of genital ulcers and prevalence of human immunodeficiency virus coinfection in 10 US cities. The Genital Ulcer Disease Surveillance Group. J Infect Dis (1998) 1.55

Significance of cytogenetic findings for the clinical outcome in patients with T-cell lymphoma of angioimmunoblastic lymphadenopathy type. J Clin Oncol (1996) 1.53

Treatment of everolimus-resistant metastatic renal cell carcinoma with VEGF-targeted therapies. Br J Cancer (2011) 1.53

Low incidence of invasive fungal infections after bone marrow transplantation in patients receiving amphotericin B inhalations during neutropenia. Ann Hematol (1994) 1.51

Double induction strategy including high dose cytarabine in combination with all-trans retinoic acid: effects in patients with newly diagnosed acute promyelocytic leukemia. German AML Cooperative Group. Leukemia (2000) 1.51

Mesenchymal stem cells for clinical application. Vox Sang (2009) 1.50

SETBP1 mutation analysis in 944 patients with MDS and AML. Leukemia (2013) 1.50

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood (2001) 1.48

Impact of adjunct cytogenetic abnormalities for prognostic stratification in patients with myelodysplastic syndrome and deletion 5q. Leukemia (2010) 1.48

Recent improvement in outcome of unrelated donor transplantation for aplastic anemia. Bone Marrow Transplant (2007) 1.47

Primary myelodysplastic syndromes: analysis of prognostic factors in 235 patients and proposals for an improved scoring system. Leukemia (1992) 1.45

Two types of acquired idiopathic sideroblastic anaemia (AISA) Br J Haematol (1990) 1.45

Pericardial effusion in chronic myelomonocytic leukemia (CMML): a case report and review of the literature. Leuk Res (2000) 1.42

Transplantation of allogeneic CD34+-selected cells followed by early T-cell add-backs: favorable results in acute and chronic myeloid leukemia. Cytotherapy (2004) 1.41

A randomized, double-blind, placebo-controlled, phase III study of filgrastim in remission induction and consolidation therapy for adults with de novo acute myeloid leukemia. The International Acute Myeloid Leukemia Study Group. Blood (1997) 1.40

The Clq receptor site on immunoglobulin G. Nature (1980) 1.40

[Severe tetraparesis as the first manifestation of a chronic lymphatic leukemia]. Dtsch Med Wochenschr (1992) 1.39

Increases of sICAM-1 during neutropenic pneumonia in leukemic patients. Leukemia (1997) 1.39

[Diagnosis and therapy of primary stomach lymphoma]. Dtsch Med Wochenschr (1998) 1.39

Changes in erythroid progenitor cell and accessory cell compartments in patients with myelodysplastic syndromes during treatment with all-trans retinoic acid and haemopoietic growth factors. Br J Haematol (1995) 1.39

Insufficient stromal support in MDS results from molecular and functional deficits of mesenchymal stromal cells. Leukemia (2013) 1.39

SF3B1 mutations in myelodysplastic syndromes: clinical associations and prognostic implications. Leukemia (2011) 1.38

Refinement of the international prognostic scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia (2005) 1.38

[Fall Congress for Integrative Medicine--model for the future]. Dtsch Med Wochenschr (2009) 1.38

Azacitidine and donor lymphocyte infusions as first salvage therapy for relapse of AML or MDS after allogeneic stem cell transplantation. Leukemia (2013) 1.37

T lymphocyte activation by staphylococcal enterotoxins: role of class II molecules and T cell surface structures. Cell Immunol (1989) 1.36

Bone marrow transplants from mismatched related and unrelated donors for severe aplastic anemia. Bone Marrow Transplant (2006) 1.36

Evolutionary relationship between the T3 chains of the T-cell receptor complex and the immunoglobulin supergene family. Proc Natl Acad Sci U S A (1987) 1.31

Utilization of Glycerol as a Hydrogen Acceptor by Lactobacillus reuteri: Purification of 1,3-Propanediol:NAD Oxidoreductase. Appl Environ Microbiol (1990) 1.31

Epidemiological features of myelodysplastic syndromes: results from regional cancer surveys and hospital-based statistics. Int J Hematol (2001) 1.30

Congenital dyserythropoietic anaemia, types I and II: aberrant pattern of erythrocyte membrane proteins in CDA II, as revealed by two-dimensional polyacrylamide gel electrophoresis. Br J Haematol (1977) 1.30

How much blood is needed? Vox Sang (2011) 1.30

Affinity and specificity of serine endopeptidase-protein inhibitor interactions. Empirical free energy calculations based on X-ray crystallographic structures. J Mol Biol (1993) 1.29

Function of the CD4 and CD8 molecules on human cytotoxic T lymphocytes: regulation of T cell triggering. J Immunol (1986) 1.27

Survival, prognostic factors and rates of leukemic transformation in 381 untreated patients with MDS and del(5q): a multicenter study. Leukemia (2012) 1.27

Distinguishing myelodysplastic syndromes (MDS) from idiopathic cytopenia of undetermined significance (ICUS): HUMARA unravels clonality in a subgroup of patients. Ann Oncol (2010) 1.26

Improved outcome in adult B-cell acute lymphoblastic leukemia. Blood (1996) 1.26

Design of heterotetrameric coiled coils: evidence for increased stabilization by Glu(-)-Lys(+) ion pair interactions. Biochemistry (1996) 1.25

Heteroplasmic point mutations of mitochondrial DNA affecting subunit I of cytochrome c oxidase in two patients with acquired idiopathic sideroblastic anemia. Blood (1997) 1.24

Age, JAK2(V617F) and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis. Leukemia (2013) 1.23

The 5q- syndrome. Hematology (2004) 1.23

Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol (2009) 1.22

Clinical and molecular characterization of early T-cell precursor leukemia: a high-risk subgroup in adult T-ALL with a high frequency of FLT3 mutations. Blood Cancer J (2012) 1.22

The human C3a receptor is expressed on neutrophils and monocytes, but not on B or T lymphocytes. J Exp Med (1997) 1.22

DNA repair genetic polymorphisms and risk of colorectal cancer in the Czech Republic. Mutat Res (2007) 1.22

Non-alpha-helical elements modulate polytopic membrane protein architecture. J Mol Biol (2001) 1.21

High levels of thrombopoietin in sera of patients with essential thrombocythemia: cause or consequence of abnormal platelet production? Ann Hematol (1998) 1.21

Consensus conference on European preparedness for haematological and other medical management of mass radiation accidents. Ann Hematol (2006) 1.21

Marrow fibrosis predicts early fatal marrow failure in patients with myelodysplastic syndromes. Leukemia (2007) 1.21

Low IPSS score and bone marrow hypocellularity in MDS patients predict hematological responses to antithymocyte globulin. Leukemia (2007) 1.20

Characterization of a new four-chain coiled-coil: influence of chain length on stability. Protein Sci (1995) 1.19

Aberrant methylation and impaired expression of the p15(INK4b) cell cycle regulatory gene in chronic myelomonocytic leukemia (CMML). Leukemia (2003) 1.19